Related Experiment Video
Updated: Oct 4, 2025
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
Fondaparinux: A cornerstone drug in acute coronary syndromes
Mohammed Yunus Khan1, Chandrashekhar K Ponde2, Viveka Kumar3
1Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad 500018, India. doctorkhan26@gmail.com.
Insights
Fondaparinux effectively manages acute coronary syndrome (ACS) by reducing ischemic events. This anticoagulant offers a safer profile with convenient dosing, minimizing bleeding risks and mortality compared to other treatments.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Acute coronary syndrome (ACS) management requires balancing antithrombotic efficacy with bleeding risk.
- Traditional anticoagulants present challenges like heparin-induced thrombocytopenia and the need for intensive monitoring.
- Novel anticoagulants are sought to improve safety and convenience in ACS treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of Fondaparinux in the management of acute coronary syndrome (ACS).
- To compare Fondaparinux with other anticoagulant strategies in ACS patients.
- To highlight the benefits of Fondaparinux regarding administration, monitoring, and adverse event profile.
Main Methods:
- Review of clinical trials, including the Organization to Assess Strategies in Ischemic Syndromes (OASIS) 5 and 6 studies.
- Meta-analysis of data comparing Fondaparinux to other anticoagulants in ACS.
- Assessment of efficacy (ischemic events) and safety (bleeding, mortality) outcomes.
Main Results:
- Fondaparinux demonstrated significant reduction in ischemic events across the ACS spectrum.
- Studies confirmed Fondaparinux's superior efficacy when used with antiplatelet agents compared to monotherapy.
- Fondaparinux showed a favorable safety profile, with reduced bleeding complications and mortality.
Conclusions:
- Fondaparinux is a highly effective anticoagulant for managing acute coronary syndrome (ACS).
- Its once-daily administration, lack of routine monitoring, and improved safety profile make it a preferred option.
- Fondaparinux offers a simplified and effective approach to ACS treatment, enhancing patient outcomes.
Abstract:
In acute coronary syndrome (ACS), the use of anticoagulants in conjunction with antiplatelet agents in the acute phase has resulted in reduced ischemic events and is more effective than either class of drug used alone. Though parenteral anticoagulation is essential at the time of diagnosis, a balance must be made between ischemic benefit and the increased risk of bleeding when prescribing anticoagulants. Adverse events associated with anticoagulants, such as heparin-induced thrombocytopenia, bleeding problems, and the need for close monitoring of anticoagulant activity, have contributed to finding agents that reduce these limitations. Studies like the Organization to Assess Strategies in Ischemic Syndromes 5 and 6 and their meta-analysis have proven the efficacy of Fondaparinux over the entire ACS spectrum. The convenience of administration (once daily), lack of monitoring, reduction in mortality, and better safety profile make Fondaparinux a simple and effective anti-coagulant for the management of ACS.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Acute Coronary Syndrome V: Nursing Management